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Clinics 
Age and sex 
71 years old male patient. 
Previous history 
Preleukemia. No previous malignancy. No inborn 
condition of note. 
Organomegaly 
No hepatomegaly, splenomegaly (Spleen appears 
enlarged measures 15.8 cm in length), no enlarged 
lymph nodes, no central nervous system involvement. 
Blood 
WBC : 112.7X 109/l 
HB : 13.3g/dl 




MPN (near 100% cellular marrow with granulocytic 
and megakaryocytic hyperplasia consistent with 
chronic myeloproliferative neoplasm). 
Immunophenotype: NA 








Date of diagnosis: 10-2004 
Treatment: Could tolerate Interferon or Hydrea and is 
on regulated dose of Busulfan. 
Complete remission :  None 
Treatment related death :  NA 
Relapse : no   
Phenotype at relapse: NA 
Status: Alive. Last follow up: 12-2010. 
Survival: 74 months 
Karyotype 
Sample: 10/2004 BM, 6/2007 PB and 12/2010 BM 
Culture time: 24 and 72 hours with overnight 
Colcemid 
Banding: GTW at 400 bands 
Results 
10/2004 BM 46,XY[20];  
6/2007 PB 46,XY[10];  
12/2010 BM 46,XY,+9,der(9;18)(p10;q10) 
[8]/46,sl,del(13)(q12q14)[cp6]/46,XY[6] 
Karyotype at Relapse: NA 
Other molecular cytogenetics technics: None 
Other Molecular Studies 
Technics: PCR 
Results: JAK2V617F mutation 
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Case 0001M : two partial karyotypes of the stemline (row1-2) 
with 2 normal chromosomes 9 a der(9;18), 13 pairs, a one 
normal chromosome 18 and arrow). Two partial karyotpes of 
the sideline (row 3-4) with a normal chromosome 9 pair, a 
der(9;18), a normal chromosome 13 and a deleted 13 (arrow) 
and a normal 18 (arrow). 
Comments 
Both the cases described in this study were followed 
for > 5 years. Case 0001M, had thrombocytosis and 
could not tolerate Interferon or Hydrea treatment and 
hence was treated with Busulfan. The patient was 
positive for JAK2 mutation (on chromosome 9). A 
recent study was to rule out transformation of MPN as 
there was myelofibrosis, splenomegaly and apparent 
progression of the disease. The der(9;18) was first 
identified in the stem line and a sideline had partial 
deletion of chromosome 13q. Case 0002M was a MDS 
case with a der(9;18) detected in the initial study and  
again when the patient was suspected to be 
transforming > 5 years later. This patient had very little 
symptoms and was not treated. 
In this report for the first time a long standing MDS 
case was found to have the der(9;18) at initial diagnosis 
and after over 5 years . Others reported with 
der(9;18)(n 7) had PV (n 3) or post PV myelofibrosis (n 
4) and one had sAML after ET. The JAK2V617F is a 
gain in function mutation on chromosome 9. Hence, the 
extra copy of 9p may exacerbate the MPN as observed 
in 0001M case. The patient had splenomegaly and also 
myelofibrosis when the patient was found with the 
der(9;18). Der(9;18) is the sole abnormality in most 
reported cases, balanced translocations or complex 
aberrant karyotypes were reported as additional 
abnormalities. Our patient had del(13) in a sideline and 
this abnormality is observed in MPN. Among the 9 
patients with der(9;18) two arose post treatment 
(present case 0001M and Andrieux et al 2003). and the 
other were at diagnosis.  
The der(9;18) supports progression of the disease in 
case 0001M but in case 0002M with MDS it reappears 
when there is suspicion of transformation and its role is 
less uncertain. 
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